Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. develops immuno-pharma therapeutics led by Ampligen (rintatolimod), a dsRNA and selective TLR3 agonist immuno-modulator under development for late-stage pancreatic cancer and other cancer, viral disease and immune-disorder indications. Company news commonly covers clinical disclosures for Ampligen, including pancreatic cancer studies with checkpoint inhibitors, intellectual-property approvals, and regulatory designations.
Updates also address financing and capital-structure actions, such as rights offerings, preferred stock and warrant terms, at-the-market equity arrangements, shareholder voting matters, governance disclosures, operating results, and public-company reporting matters including audit and going-concern disclosures.
AIM ImmunoTech (NYSE American: AIM) regained compliance with NYSE American continued listing standards for stockholders’ equity.
Through May–June 2026 warrant exercises and equity offerings, AIM raised about $8.5 million/b] in gross proceeds and believes stockholders’ equity now exceeds the
AIM ImmunoTech (NYSE American: AIM) entered definitive agreements for a registered direct offering and concurrent private placement priced at-the-market for approximately $2.65 million in gross proceeds.
The company will issue 2,554,119 registered shares, 2,554,119 unregistered shares or pre-funded warrants, and Class J warrants for up to 10,216,476 shares to fund clinical manufacturing, current and planned Phase 3 trials, and working capital.
AIM (NYSE American:AIM) reported positive mid-year interim progress from the Phase 2 DURIPANC study evaluating Ampligen (rintatolimod) plus AstraZeneca’s Imfinzi (durvalumab) in metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX.
The final patient has been enrolled, and AIM remains on track for a planned December 2026 evaluation of the primary endpoint, Clinical Benefit Rate (CBR) at 6 months. DURIPANC follows a 57-subject Named Patient Program where Ampligen monotherapy was associated with median survival of 19.7 months versus 8.6 months for standard of care, with reported quality-of-life improvements.
In NPP subjects with Neutrophil/Lymphocyte ratios <4.5, overall median survival was 34.8 months versus 12.5 months for historical controls. AIM is planning a potential pivotal Phase 3 trial of Ampligen with a PD-1 inhibitor focused on overall and progression-free survival.
AIM ImmunoTech (NYSE American:AIM) released a Virtual Investor “What This Means” video discussing Ampligen in Ebola virus disease preparedness, especially the Bundibugyo (BDBV) strain.
Management reviews preclinical Biosafety Level 4 data, Ampligen’s immune‑modulating mechanism, orphan drug designations, and updated Ebola-focused investor materials.
AIM ImmunoTech (NYSE American:AIM) reported completion of enrollment in its Phase 2 DURIPANC trial of Ampligen plus Imfinzi for metastatic pancreatic cancer, more than one month ahead of the July 2026 target. Final subject dosing is planned for mid-June, with Ampligen dosing completion expected in August and primary endpoint Clinical Benefit Rate evaluation planned for December 2026.
The program is supported by positive interim DURIPANC data, orphan drug designations in the US and Europe, published Dutch Named Patient Program results, and clinical experience in over 100 Ampligen-treated pancreatic cancer patients.
AIM ImmunoTech (NYSE American: AIM) entered definitive agreements for a registered direct offering of 7,519,351 common shares (or equivalents) at $0.325 per share, for expected gross proceeds of about $2.4 million before fees.
Concurrent with this, AIM will privately issue Series I warrants to purchase up to 15,038,702 shares at $0.325, exercisable for five years subject to stockholder approval. Closing is expected around May 21, 2026. According to AIM ImmunoTech, net proceeds will fund clinical drug supply manufacturing, planned Phase 3 trial activities, and working capital.
AIM ImmunoTech (NYSE American:AIM) reported a significant rise in stockholder equity and an extension of its key promissory note to June 30, 2027.
Equity reached about $2.1 million as of March 31, 2026, up roughly $11.9 million from a prior deficit, supporting its pancreatic cancer development strategy.
AIM ImmunoTech (NYSE American: AIM) released a Virtual Investor KOL segment highlighting Ampligen (rintatolimod) data in late-stage pancreatic cancer. Professor Casper H.J. van Eijck and CEO Thomas K. Equels discuss mechanism, clinical results, strategy and regulatory plans.
Data from an Erasmus MC Named Patient Program showed progression-free survival of 12.6 vs 8.6 months and overall survival of 19.7 vs 12.5 months versus historical controls, with larger gains in selected biomarker subgroups. Ampligen is also being studied in the Phase 2 DURIPANC trial with AstraZeneca’s Imfinzi, with a mid-year 2026 update and enrollment completion expected in June 2026. Multiple peer-reviewed publications describe Ampligen’s pancreatic cancer research.
AIM ImmunoTech (NYSEAM:AIM) announced that holders will exercise existing Class A–F warrants to buy up to 8,719,928 common shares at $0.48 per share for gross proceeds of approximately $4.2 million, before fees. The company plans to use net proceeds for working capital and general corporate purposes.
In exchange, exercising holders will receive private Replacement Warrants exercisable, upon stockholder approval, into up to 17,439,856 shares at $0.60 per share for five years. The offering is expected to close on or about May 8, 2026, subject to customary closing conditions.
AIM ImmunoTech (NYSE American: AIM) reported final primary endpoint results from a UPMC Phase 2 trial combining Ampligen (rintatolimod) with pembrolizumab and cisplatin in recurrent ovarian cancer. Topline: 50% ORR, 21% complete responses, 79% clinical benefit rate, median OS 32.5 months, durable responses >70 months, and no Grade 4–5 toxicities. Additional secondary endpoint data collection is expected to complete in January 2027.